Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's  (NYSE:MRK) Keytruda for renal cell carcinoma (RCC).

  • The opinion covers Keytruda as monotherapy for the adjuvant treatment of RCC patients at increased risk of recurrence following nephrectomy or resection of metastatic lesions.
  • The opinion is based on Phase 3 KEYNOTE-564 trial data, in which Keytruda reduced the risk of disease recurrence or death by 32% compared to placebo. 
  • The European Commission will now review the CHMP's recommendation for marketing authorization in the European Union, and a final decision is expected in Q1 of 2022.
  • Price Action: MRK shares are up 0.92% at $76.61 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.